Use of quetiapine in elderly patients

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 13, 2002, Pages 21-26

  Tariot, Pierre N ^a   Ismail, M Saleem ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR; QUETIAPINE;

ANTICHOLINERGIC EFFECT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEWY BODY; NURSING HOME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RECEPTOR BINDING; SCHIZOPHRENIA; SENESCENCE; SOMNOLENCE; VERTIGO;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLINICAL TRIALS; DEMENTIA; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMANS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0036460267     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Targum SD, Abbott JL. Psychoses in the elderly: A spectrum of disorders. J Clin Psychiatry 1999;60(suppl 8):4-10
2. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998;59(suppl 1):5-10
3. Soares JC, Gershon S. Therapeutic targets in late-life psychoses: Review of concepts and critical issues. Schizophr Res 1997;27:227-239
4. Chan YC, Pariser SF, Neufeld G. Atypical antipsychotics in older adults. Pharmacotherapy 1999;19:811-822
5. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60(suppl 8):29-41
6. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: Effects on cognition and implications for use. Drugs Aging 2001;18:45-61
7. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63(suppl 4):12-19
8. Peyser CE, Naimark D, Zuniga R, et al. Psychoses in Parkinson's disease. Semin Clin Neuropsychiatry 1998;3:41-50
9. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999;60(suppl 8):42-53
10. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-211
11. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
12. Roberts VJ, Juncos JL, Wood CD, et al. Quetiapine for psychosis in patients with Parkinson's disease. Presented at the 32nd annual meeting of the American Society of Consultant Pharmacists Senior Care; Nov 7-10, 2001; Chicago, Ill
13. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487
14. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60
15. Juncos JL, Jewart RD, Neparizde N, et al. Long-term prognosis of hallucinating Parkinson's disease patients treated with quetiapine or clozapine. Presented at the 54th American Academy of Neurology Annual Meeting; April 13-20, 2002; Denver, Colo
16. Juncos JL, Evatt ML, Jewart D. Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis [abstract]. Neurology 1998;50 (suppl 4):A70-A71
17. Juncos JL, Yeung PP, Sweitzer D, et al. Quetiapine improves psychotic symptoms associated with Parkinson's disease. Presented at the 7th International Congress on Schizophrenia Research; April 17-21, 1999; Santa Fe, NM
18. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-144
19. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219
20. Evatt ML, Jewart DR, Juncos JL. "Seroquel" (ICI 204,636) treatment of psychosis in parkinsonism [abstract]. Mov Disord 1996;11:595
21. Friedman J, Fernandez HH, Jacques C. Quetiapine for the treatment of dopamimetic psychosis in Parkinson's disease. Presented at the 152nd Annual Meeting of the American Psychiatric Association; May 15-20, 1999; Washington, DC
22. Juncos JL, Roberts VJ, Evatt ML, et al. Long-term improvement in psychotic symptoms and cognition with quetiapine in Parkinson's disease patients who failed treatment with other atypical antipsychotic agents. Presented at the 14th Annual Meeting of the American Association for Geriatric Psychiatry: Feb 24-26, 2001; San Francisco, Calif
23. Fernandez HH, Lannon MC, Friedman JH, et al. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:579-581
24. Fernandez HH, Trieschmann ME, Burke MA, et al. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515
25. Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: Findings challenge traditional concepts. Harv Rev Psychiatry 2001;9:51-58
26. Wynn Owen PA, Castle DJ. Late-onset schizophrenia: Epidemiology, diagnosis, management and outcomes. Drugs Aging 1999;15:81-89
27. Salzman C, Tune L. Neuroleptic treatment of late-life schizophrenia. Harv Rev Psychiatry 2001;9:77-83
28. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001;23:1839-1854
29. Mintzer J, Mullen J, Sweitzer D. Extrapyramidal symptoms in elderly patients treated with quetiapine or risperidone. Presented at the 9th International Congress of the International Psychogeriatric Association; Sept 9-14, 2001; Nice, France
30. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1085
31. Vinogradov S, Salzman C, Pultz JA, et al. Long-term safety, tolerability and clinical improvement with quetiapine in elderly patients with schizophrenia. Presented at the 10th Biennial Winter Workshop on Schizophrenia; Feb 5-11, 2000; Davos, Switzerland
32. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000;13:28-32
33. Tarior PN. Treatment of agitation in dementia. J Clin Psychiatry 1999;60 (suppl 8):11-20
34. Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: The role of newer antipsychotics. Drugs Aging 1999;14:41-54
35. Rosenquist K, Tariot PN, Loy R. Treatment for behavioral and psychological symptoms in Alzheimer's disease. In: Ames D, Burns A, O'Brien J, eds. Dementia. 2nd Ed. London, England: Chapman & Hall; 2000:571-601
36. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154-1166
37. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience. Drugs Aging 2002;19:257-276
38. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 1992;305:673-678
39. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology 1996; 47:1113-1124
40. Tariot P, Schneider L, Katz IR, et al. Quetiapine in nursing home residents with Alzheimer's dementia and psychosis [poster]. Presented at the 15th annual meeting of the American Association for Geriatric Psychiatry; Feb 24-27, 2002; Orlando, Fla
41. Schneider L, Yeung PP, Sweitzer D, et al. Quetiapine may reduce hostility in patients with psychoses related Alzheimer's disease. Presented at the 7th International Congress on Schizophrenia Research; April 17-21, 1999; Santa Fe, NM
42. Elliot T, Elliott A. Quetiapine in the management of psychosis in dementia with Lewy bodies: Preliminary findings of a pilot study. Presented at the Montreux meeting; June 20-21, 2001; Montreux, Switzerland
43. Baskys A, Davis P. Atypical antipsychotic quetiapine in the treatment of the psychosis associated with Lewy body dementia. Presented at the 8th International Conference on Alzheimer's Disease and Related Disorders; July 20-25, 2002; Stockholm, Sweden
44. Parsa M, Greenway H, Bastani B. Quetiapine in the treatment of psychosis in patients with Parkinson's disease and dementia (Lewy body disease variant). Presented at the Annual Meeting of the American Neurological Association; Sept 30-Oct 3, 2001; Chicago, Ill
45. Juncos JL, Jewart DR, Gearing M, et al. Quetiapine treatment of psychotic symptoms in Lewy body dementia: Long-term experience in ten patients with three pathologically confirmed cases. Presented at the 125th annual meeting of the American Neurological Association; Oct 15-18, 2000; Boston, Mass
46. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002;16:128-130
47. Parsa MA, Poggi EV, Barte L, et al. Treatment of dementia patients with psychotic and behavioral symptoms with quetiapine and donepezil. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La